BLISSGVS vs WANBURY: Stock Comparison

Bliss GVS Pharma Limited vs Wanbury Ltd

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Bliss GVS Pharma Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Wanbury Ltd shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 5 of 13 scored metrics and WANBURY on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BLISSGVS is the larger company
₹4,757 Cr vs ₹1,091 Cr
P/E Ratio
WANBURY has a lower P/E
0x vs 37.17x
P/B Ratio
WANBURY has a lower P/B
0x vs 4.03x
EPS
WANBURY has higher earnings per share
₹13.1 vs ₹11.99
Dividend Yield
BLISSGVS has a higher dividend yield
0.19% vs 0%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs -19.2%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs 0%
Qtr Sales Growth
WANBURY has stronger quarterly sales growth
24.5% vs 13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSWANBURY
Live Price₹527.1₹312.45
Day Change0.68%-5.1%
Volume3.93 L2.85 L
52-Week High₹553₹358.85
52-Week Low₹118₹161.5
Distance from 52W High-4.68%-12.93%

Valuation

MetricBLISSGVSWANBURY
Market Cap₹4,757 Cr₹1,091 Cr
P/E Ratio37.17x0x
P/B Ratio4.03x0x
EPS₹11.99₹13.1
Book Value₹107.21₹18.1
Dividend Yield0.19%0%

Growth

MetricBLISSGVSWANBURY
Revenue Growth (TTM YoY)29.8%-19.2%
EPS Growth (TTM YoY)124.7%0%
Qtr Sales Growth13%24.5%
Qtr Profit Growth108%1,197%

Profitability & Leverage

MetricBLISSGVSWANBURY
ROE0%76.5%
ROCE11.7%36.6%
Net Margin13.93%10.17%
Operating Margin12.82%14%
Debt to Equity1.77x3.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBLISSGVSWANBURY
Promoter Holding35.01% 0.35 pp34.36%
FII Holding8.07% 2.38 pp0.89% 0.3 pp
DII Holding9.47% 4.43 pp0.06% 0.06 pp
Public Holding47.45% 1.7 pp56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.